Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAMIRIS: Ramucirumab plus FOLFIRI versus Ramucirumab plus Paclitaxel in advanced or metastatic gastric or gastroesophageal junction adenocarcinoma after one prior palliative chemotherapy
2015-005171-24Phase 2Active
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of ramucirumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and gastric cancer (GC) (2 arms), sponsored by Institut für Klinische Krebsforschung. Primary endpoints: Primary endpoint phase II and Primary objectives phase III. Started Sep 2016; status: active.
02
Drugs
ramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomagastric cancer (GC)
Beyond the preview
Go deeper on 2015-005171-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005171-24.